Johnson & Johnson

JNJ

Market cap $424B

Overview Fund Activity

176.19 USD

+2.03

1.17%

At close Updated Sep 19, 4:00 PM EDT

Pre-market

After hours

174.95

-1.24

0.7%

1 day

1.17%

5 days

-0.88%

1 month

-0.91%

3 months

17.62%

6 months

8.1%

Year to date

22.34%

1 year

6.9%

5 years

21.43%

10 years

89.19%

About: Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Employees: 139,800

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,466 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

24% more call options, than puts

Call options by funds: $3.06B | Put options by funds: $2.48B

1.92% more ownership

Funds ownership: 70.98% [Q1] → 72.9% (+1.92%) [Q2]

3% less first-time investments, than exits

New positions opened: 172 | Existing positions closed: 177

2% less funds holding

Funds holding: 4,090 [Q1] → 4,010 (-80) [Q2]

6% less capital invested

Capital invested by funds: $283B [Q1] → $267B (-$16.5B) [Q2]

14% less repeat investments, than reductions

Existing positions increased: 1,596 | Existing positions reduced: 1,860

43% less funds holding in top 10

Funds holding in top 10: 225 [Q1] → 128 (-97) [Q2]

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$167

5% downside

Avg. target

$184

4% upside

High target

$200

14% upside

8 analyst ratings

3 positive

38%

5 neutral

63%

0 negative

0%

JP Morgan Michael Weinstein	$200	Neutral Maintained	16 Sep 2025
Citigroup Joanne Wuensch	$200	Buy Maintained	21 Aug 2025
Barclays Matt Miksic	$176	Equal-Weight Maintained	17 Jul 2025
RBC Capital Shagun Singh	$185	Outperform Maintained	17 Jul 2025
Guggenheim Vamil Divan	$167	Neutral Maintained	17 Jul 2025
UBS Danielle Antalffy	$190	Buy Maintained	17 Jul 2025
Morgan Stanley Terence Flynn	$176	Equal-Weight Maintained	17 Jul 2025
B of A Securities Tim Anderson	$175	Neutral Maintained	17 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 68 articles about JNJ published over the past 30 days

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA® achieved significant rates of clinical remission and endoscopic improvement versus placebo at Week 12 with a subcutaneous induction regimen, consistent with IV induction Johnson & Johnson is initiating a head-to-head study seeking to demonstrate the superiority of TREMFYA® vs. Skyrizi® (risankizumab) in Crohn's disease, based on the confidence in the clinical profile HORSHAM, Pa.

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma

100 percent of evaluable patients achieved minimal residual disease (MRD) negativity following induction therapy in updated results from the Phase 2 MajesTEC-5 study TORONTO , Sept. 19, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that an investigational immune-based induction regimen with TECVAYLI® (teclistamab-cqyv) and DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) demonstrated meaningful clinical efficacy in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM).

TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma

Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)

Pending the European Commission's final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive

Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)

Zacks Investment Research

Top Wide-Moat Stocks Worth a Look for Sustainable Growth

MSFT, JNJ, NKE and SPGI use strong moats to fend off rivals and deliver consistent returns amid market shifts.

Top Wide-Moat Stocks Worth a Look for Sustainable Growth

The Motley Fool

8 Dividend Growth Stocks Every Investor Should Consider

Forget the dividend darlings everyone already owns -- the real money in income investing comes from companies raising their payouts faster than inflation while keeping enough cash to reinvest in growth.

8 Dividend Growth Stocks Every Investor Should Consider

Zacks Investment Research

Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts

Johnson & Johnson (JNJ) reached $174.16 at the closing of the latest trading day, reflecting a -1.72% change compared to its last close.

Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts

Zacks Investment Research

J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why

J&J sees Innovative Medicines growth in 2025, fueled by oncology and immunology drugs, despite steep Stelara sales erosion.

J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why

J&J's experimental psoriasis drug shows promise against Bristol's treatment

Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.

J&J's experimental psoriasis drug shows promise against Bristol's treatment

Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed sustained skin clearance and favorable safety profile in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD study Robust findings continue to demonstrate the potential of icotrokinra to disrupt the treatment paradigm to set a new standard for treating patients with moderate-to-severe plaque psoriasis SPRING HOUSE, Pa. , Sept. 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies which assessed the superiority of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis.

Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis

3 Dividend Stocks to Hold Through Market Volatility This Fall

Stocks are rallying on the expectation that the Federal Reserve will cut interest rates by 25 basis points in September. That should be positive for corporate earnings.

3 Dividend Stocks to Hold Through Market Volatility This Fall

See News Rankings

Charts implemented using Lightweight Charts™